Genitourinary Cancers (GU)
Clinical Updates
Balversa's FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer
Should Surgery Be Considered for Oligometastatic Bladder Cancer?
New Combination Of Immunotherapy And Chemotherapy Could Effectively Treat Metastatic Bladder Cancer
The Latest Efforts to Preserve the Bladder
Integrating Genetic Testing and PARP Inhibitors in Prostate Cancer Management
Withdrawal of Durvalumab for Advanced Bladder Cancer “a Disappointing Loss”
Why Don't Checkpoint Inhibitors Work for More Bladder Cancer Patients?
Excitement Around Immune Checkpoint Inhibitors in the Neoadjuvant Setting for Bladder Cancer
